<DOC>
	<DOCNO>NCT01208207</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability two dos etoricoxib compare naproxen treatment ankylose spondylitis ( AS ) . The primary objective evaluate improvement Spinal Pain Intensity 6 week treatment etoricoxib 90 mg 60 mg compare naproxen ; evaluate improvement Spinal Pain Intensity 6 week treatment etoricoxib 90 mg compare etoricoxib 60 mg. Additionally add benefit increase dose etoricoxib 60 mg 90 mg assess second part study . The primary hypothesis improvement Spinal Pain Intensity visual analog scale ( VAS ) measure time-weighted average ( TWA ) change baseline 6 week treatment Part I etoricoxib 90 mg 60 mg daily inferior naproxen 1000 mg .</brief_summary>
	<brief_title>A Two-Part 26-Week Study Etoricoxib Treatment Ankylosing Spondylitis ( AS ) ( MK-0663-108 )</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Has definite diagnosis Ankylosing Spondylitis ( AS ) per Modified New York Criteria make least 6 month prior screen Has history positive therapeutic benefit nonsteroidal antiinflammatory drug ( NSAIDs ) regular use NSAIDS past 30 day Has score Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) Question 2 screen visit &lt; 77 mm Must demonstrate sufficient `` flare '' worsen AS pain Is general good health ( AS ) Has approve nonstudy antirheumatic therapy stable dosing AND anticipate undergo change within first 6 week protocol Has inflammatory arthritis ( eg , rheumatoid arthritis , psoriatic arthritis , crystalinduced arthritis , spondyloarthropathy , diffuse idiopathic skeletal hyperostosis [ DISH ] ) , polymyalgia rheumatica , history septic arthritis intraarticular fracture study joint , Wilson 's disease , hemachromatosis , ochronosis , primary osteochondromatosis Has acute peripheral articular disease ( onset within 4 week prior screen ) active ( painful swollen ) peripheral arthritis Has history gastric biliary surgery , small intestine surgery cause clinical malabsorption Has active peptic ( gastric duodenal ) ulcer history inflammatory bowel disease Has undergone coronary artery bypass graft surgery ( CABG ) , angioplasty , cerebrovascular accident transient ischemic attack within past 6 month active ischemic heart disease , cerebrovascular disease , peripheral vascular disease Has Class IIIV congestive heart failure Has uncontrolled hypertension Has history neoplastic disease , except adequately treat basal cell carcinoma carcinoma situ cervix , malignancy successfully treat ≥ 5 year prior screen Has history leukemia , lymphoma , malignant melanoma , myeloproliferative disease Allergy etoricoxib naproxen , history significant clinical laboratory adverse experience associate etoricoxib naproxen Has history family history inherit acquire bleed disorder Is consider morbidly obese demonstrates significant health problem stem obesity , would confound study participation interpretation study result Is pregnant , breastfeeding , expect conceive study Has clinical diagnosis hepatic insufficiency define ChildPugh score ≥ 5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>